Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP)

In the phase 3 ASPECT-NP trial (NCT02070757), ceftolozane/tazobactam (C/T) was noninferior to meropenem for treatment of Gram-negative ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (vHABP/VABP). Here, we report outcomes in participants from ASPECT-NP...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Huntington, Jennifer A., Yu, Brian, Li, Linping, Jensen, Erin, Bruno, Christopher, Boakye, Mathew, Zhang, Zufei, Gao, Wei, Feng, Hwa-Ping, Rhee, Elizabeth
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2020
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7674039/
https://ncbi.nlm.nih.gov/pubmed/32988827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00731-20
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados